RegenLab USA, Inc. (RGNA)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	54.26M +1.6%
Net Income	-1.14M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About RGNA

RegenLab is a science-driven regenerative medicine company originally founded in Switzerland and now structured under RegenLab USA, our U.S.-based holding entity. We operate through a fully integrated platform with three manufacturing sites and dedicated R&D and clinical teams based in New Jersey (USA), Paris (France), and Monthey (Switzerland). Across these sites, we maintain full control of the development and industrialization cycle, including GMP manufacturing, clinical and regulatory affairs, and global IP management. RegenLab is the holde...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 200
• Stock Exchange: NASDAQ
• Ticker Symbol: RGNA
• Website: https://regenlabusa.com/

Financial Performance

Data Source: SEC filings Last updated: Oct 2, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error